Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against ADC Therapeutics SA. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT). Investors who purchased ADC securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether ADC has violated federal securities laws.
ADC Investigation Details
On June 3, 2026, ADC “announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).” Although ADC’s treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared to the nine deaths recorded for the immunotherapy arm. Following this news, ADC’s stock price dropped $2.05 per share, or 66.56%, over the following two trading sessions, to close at $1.03 per share on June 5, 2026.
What’s Next for ADC Investors?
If you are aware of any facts relating to this investigation or purchased ADC securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
ADCT — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”